

Supplementary Table: Demographics and clinical characteristics of paraneoplastic MAP1B-IgG neuropathy in comparison to ANNA1-IgG neuropathy

	MAP1B-IgG only (25)	ANNA1-IgG only (17)	p-value
Age, median (range)	69 (22-82)	59 (22-73)	0.018
Female (%)	8 (32)	11 (65)	0.037
Smoking (%)	11 (100)	14 (88)	NS
Malignancy (%)	16 (89)	13 (76)	NS
SCC (%)	11 (69)	11 (65)	NS
Neuropathy as initial symptom (%)	18 (75)	15 (88)	NS
Weakness (%)	15 (63)	12 (75)	NS
Symmetry (%)	12/19 (63)	13 (76)	NS
Subacute onset (%)	9/19 (47)	2 (12)	0.031
Sensory neuronopathy (%)	7 (28)	13 (76)	0.004
Polyradiculoneuropathy^a (%)	13 (52)	2 (12)	0.0504
Neuropathic pain (%)	5 (20)	10 (63)	0.023
CNS involvement (%)	12 (48)	10 (59)	NS
Autonomic dysfunction (%)	5 (20)	12 (75)	0.003
GI dysmotility (%)	5 (20)	7 (47)	NS
Myelopathy (%)	3 (13)	2 (13)	NS

Abbreviation: ANNA1; anti-nuclear neuronal antibody-1, CRMP5; collapsin response-mediator protein-5, CSF; cerebrospinal fluid, IgG; immunoglobulin G, MAP1B; Microtubule-Associated Protein 1B, NS; not significant, SCC; small cell carcinoma, WBC; white blood cell

^aNo structural or compressive etiology for radiculopathy